GENE THERAPY SYSTEMS

Brand Owner Address Description
AMT AMSTERDAM MOLECULAR THERAPEUTICS (AMT) IP B.V. Meibergdreef 61 Amsterdam 1105BA Netherlands Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and call therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders, single gene disorders and cancers; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers;AMERDAM MOLECULAR THERAPEUTICS;Nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cell transformed by viral vectors, gene therapy vectors and nucleic acid delivery vectors for other than medical and veterinary purposes; chemical reagents for scientific or research use, namely, nucleic acids and vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes;Laboratory research in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry; product development and consultancy in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. A nucleic acid encoding a promoter and comprising a nucleic acid sequence of SEQ ID NO:1, fragments and/or variants thereof, for use in gene therapy derived from the Herpesvirus saimiri (HVS) ORF73 (ECLFI) gene. The invention also includes a gene therapy system and an HVS vector system including the promoter.